Skip to main content
RELMADA THERAPEUTICS, INC. logo

RELMADA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · RLMD ISIN · US75954H1005 LEI · 549300217EASRZ9JSF81 US Professional, scientific and technical activities
Open in API
Filings indexed 582 across all filing types
Latest filing 2015-01-16 Director's Dealing
Country US United States of America
Listing US RLMD

About RELMADA THERAPEUTICS, INC.

https://www.relmada.com/

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing novel therapies. The company's lead program is NDV-01, a sustained-release, intravesical formulation of gemcitabine and docetaxel for the treatment of non-muscle invasive bladder cancer. The formulation is designed for gradual drug release over 10 days to enhance local exposure and minimize systemic toxicity. Relmada's pipeline also includes Sepranolone, which is being developed for compulsive disorders. Following positive proof-of-concept data in Tourette’s syndrome, the company is planning a Phase 2 study of Sepranolone in Prader-Willi Syndrome, a rare genetic disorder.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2015-01-16 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-01-16 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-01-16 English
OWNERSHIP DOCUMENT
Director's Dealing
2015-01-16 English
REGISTRATION OF CERTAIN CLASSES OF SECURITIES
Regulatory Filings Classification · 100% confidence The document is a Form 8-A filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It includes descriptions of securities, references to articles of incorporation, bylaws, and exhibits related to the registration. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or other specific report types. It is also relatively short (4005 characters) and serves as a formal registration statement rather than a report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2015-01-06 English
PROSPECTUS
Capital/Financing Update Classification · 95% confidence The document is a detailed prospectus filed pursuant to Rule 424(b)(3) related to the sale of common stock by selling stockholders. It includes extensive information about the company's business, risk factors, management discussion and analysis, executive compensation, securities description, and plan of distribution. The document is not a financial report like an annual or quarterly report, nor is it an earnings release or a management discussion standalone. It is a registration/prospectus document related to capital raising and share sales by existing shareholders. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes. The document length (15,000 characters) and content confirm it is a full prospectus, not a brief announcement or regulatory filing. Therefore, the correct classification is CAP with high confidence.
2014-12-31 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.